381Torres-Roca JF. A molecular assay of tumor radiosensitivity: a roadmap towards biology-based
personalized radiation therapy. Per Med. 2012;9:547–57.
Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving
toward personalized medicine. Ann Transl Med. 2014;2:108.
Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defi nes chemoresistance in ovarian
cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013;110:9845–50.
Verhaak R, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous
ovarian carcinoma. J Clin Invest. 2013;123:517–25.
Villanueva A, Toffanin S, Llovet JM. Linking molecular classifi cation of hepatocellular carcinoma
and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444–53.
Wallwiener M, Riethdorf S, Hartkopf AD, et al. Serial enumeration of circulating tumor cells
predicts treatment response and prognosis in metastatic breast cancer: a prospective study in
393 patients. BMC Cancer. 2014;14:512.
Weichselbaum RA, Ishwaran H, Yoon T, et al. An interferon-related gene signature for DNA dam-
age resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc
Natl Acad Sci U S A. 2008;105:18490–5.
Weinstein JN. Spotlight on molecular profi ling: “Integromic” analysis of the NCI-60 cancer cell
lines. Mol Cancer Ther. 2006;5:2601–5.
Wheeler CJ, Black KL. DCVax-brain and DC vaccines in the treatment of GBM. Expert Opin
Investig Drugs. 2009;18:509–19.
Wilkerson MD, Yin X, Walter V, et al. Differential pathogenesis of lung adenocarcinoma subtypes
involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS
One. 2012;7(5):e36530.
Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol. 2009;5:763–74.
Worsham MJ, Ali H, Dragovic J, Schweitzer VP. Molecular characterization of head and neck
cancer: how close to personalized targeted therapy? Mol Diagn Ther. 2012;16:209–22.
Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase
inhibitor ibrutinib. N Engl J Med. 2014;370:2286–94.
Wu K, Nie Y, Guo C, et al. Molecular basis of therapeutic approaches to gastric cancer.
J Gastroenterol Hepatol. 2009;24:37–41.
Wu LY, Liu T, Hopkins MR, et al. Chemoaffi nity capture of pre-targeted prostate cancer cells with
magnetic beads. Prostate. 2012;72:1532–41.
Yadav AK, Renfrow JJ, Scholtens DM, et al. Monosomy of chromosome 10 associated with dys-
regulation of epidermal growth factor signaling in glioblastomas. JAMA. 2009;302:276–89.
Yang X, Zhou J, Weidong C, et al. 14-3-3zeta positive expression is associated with a poor prog-
nosis in patients with Glioblastoma. Neurosurgery. 2011;68:932–8.
Yang JS, Li BJ, Lu HW, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel bio-
markers in non-small cell lung cancer screening. Tumour Biol 14 Dec 2014 [Epub ahead of
print].
Yeh IT, Martin MA, Robetorye RS, et al. Clinical validation of an array CGH test for HER2 status
in breast cancer reveals that polysomy 17 is a rare event. Mod Pathol. 2009;22:1169–75.
Yoo BK, Gredler R, Vozhill N, et al. Identifi cation of genes conferring resistance to 5-fl uorouracil.
Proc Natl Acad Sci U S A. 2009;106:12938–43.
Yuan H, Myers S, Wang J, et al. Use of reprogrammed cells to identify therapy for respiratory
papillomatosis. N Engl J Med. 2012;367:1220–7.
Zhao H, Jin G, Cui K, et al. Novel modeling of cancer cell signaling pathways enables systematic
drug repositioning for distinct breast cancer metastases. Cancer Res. 2013;73:6149–63.
Zhou Y, Barlogie B, Shaughnessy Jr JD, et al. The molecular characterization and clinical manage-
ment of multiple myeloma in the post-genome era. Leukemia. 2009;23:1941–56.
Zhu H, Acquaviva J, Ramachandran P, et al. Oncogenic EGFR signaling cooperates with loss of
tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A. 2009;106:
2712–6.
References